The project is funded with a €10.5m grant from the European Commission’s Framework Programme 7.
The AP device will use a continuous glucose monitor (CGM) and an insulin infusion pump, and along with a software algorithm, the system will calculate how much insulin to deliver at any time in response to blood glucose levels.
In the final year of the 4-year project (ending 2014), the performance of the newly created AP device, including remote monitoring facilities, will be compared with standard intensive insulin therapy in daily life in a multinational controlled trial.
Triteq commercial director Steve Lane said the company’s role now is to apply electronic design expertise to develop a system for suitable clinical trials.
"This will bring together the CGM and insulin infusion pump into a single device, with the ultimate aim of having a single access point through the patient’s skin. Different software algorithms will be built into the system to interpret the data gathered by the CGM and automatically control insulin dosage and delivery," Lane said.
The AP@home consortium includes academic partners (Universities of Cambridge, Padova, Pavia, University Hospitals of Amsterdam and Montpellier, Medical University Graz, EPF Lausanne) and industrial partners (Profil Institut für Stoffwechselforschung, Sensile Medical, STMicroelectronics, 4a engineering and Triteq).
